Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Advances in Pharmacology of Pain and Inflammation
share announcement

Advances in Pharmacology of Pain and Inflammation

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery, Development and Delivery".

Deadline for manuscript submissions: closed (30 June 2026) | Viewed by 5714

Editors

Prof. Dr. Fernanda Regina de Castro Almeida

E-Mail Website
Guest Editor
Post Graduate Program in Pharmacology, Laboratory of Pain Pharmacology/Laboratory of Inflammation Pharmacology, Medicinal Plants Research Center, Federal University of Piauí—UFPI, Teresina 64049-550, Brazil
Interests: pharmacology of pain; chronic pain
Dr. Francisco De Assis Oliveira

E-Mail Website
Guest Editor
Post Graduate Program in Pharmacology, Laboratory of Pain Pharmacology/Laboratory of Inflammation Pharmacology, Medicinal Plants Research Center, Federal University of Piauí—UFPI, Teresina 64049-550, Brazil
Interests: chronic inflammatory diseases and inflammatory conditions of the respiratory tract

Special Issue Information

Dear Colleagues,

Globally, 7 of the 10 leading causes of death in recent years were non-communicable diseases, accounting for approximately 38% of all deaths or 68% of the 10 leading causes. These include several painful (oncological pain and neuropathies) and inflammatory (diseases and cancers of the respiratory tract) conditions. The treatment of neuropathic pain is challenging due to its heterogeneous etiologies, lack of objective diagnostic tools, and resistance to classic analgesic drugs. Recommended first-line treatments include gabapentinoids, tricyclic antidepressants and selective serotonin, and norepinephrine reuptake inhibitors.

The inflammatory response involves cellular effectors and chemicals that participate in a wide variety of diseases, such as Chronic Obstructive Pulmonary Disease (COPD). This disease is characterized by the infiltration of inflammatory cells into the airways, resulting in the activation of proteolytic enzymes and proteinases, leading to the destruction of the alveolar structure (pulmonary emphysema). Pharmacological treatment involves the use of β2 adrenergic agonists, muscarinic receptor antagonists, phosphodiesterase-4 enzyme inhibitors, and corticosteroids, which do not prevent disease progression or reduce mortality.

This Special Issue aims to provide a space for the exploration of new therapies for the treatment of neuropathies, cancer pain, and inflammatory diseases of the respiratory tract, such as pulmonary emphysema.

Authors are invited to contribute with preclinical research articles and systematic reviews on the investigation of natural products for the treatment of chronic pain (neuropathies and cancer pain) and inflammation of the respiratory tract (pulmonary emphysema).

Prof. Dr. Fernanda Regina de Castro Almeida
Dr. Francisco De Assis Oliveira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • chronic pain
  • neuropathies
  • oncological pain
  • anti-inflammatory activity
  • pulmonary emphysema

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1835 KB  
Article
Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs
by Charles Lynde, Louis Flamand, Vincent McCarty and John Sampalis
Biomedicines 2025, 13(12), 2938; https://doi.org/10.3390/biomedicines13122938 - 29 Nov 2025
Viewed by 1287
Abstract
Background/Objectives: Persistent inflammation driven by cytokines/chemokines plays a crucial role in the pathogenesis of numerous chronic inflammatory and autoimmune conditions, including rheumatoid arthritis, atopic dermatitis, and ulcerative colitis. Current therapeutic agents often present limitations due to adverse effects. Thykamine™, a new plant-derived [...] Read more.
Background/Objectives: Persistent inflammation driven by cytokines/chemokines plays a crucial role in the pathogenesis of numerous chronic inflammatory and autoimmune conditions, including rheumatoid arthritis, atopic dermatitis, and ulcerative colitis. Current therapeutic agents often present limitations due to adverse effects. Thykamine™, a new plant-derived multi-target drug, has demonstrated promising anti-inflammatory effects and a favorable safety profile in clinical settings. This study aimed to compare the in vitro chemokine-inhibitory potency of Thykamine™, a novel plant-derived anti-inflammatory compound, with that of six marketed corticosteroid and non-steroidal agents. Methods: This study compared the in vitro potency of Thykamine™ against widely prescribed anti-inflammatory agents, including corticosteroids (betamethasone, clobetasol, hydrocortisone, prednisone) and non-steroidal therapies (crisaborole, pimecrolimus). Potency was assessed by measuring the inhibition of key pro-inflammatory chemokines: MCP-1, MIP-1α, MIP-1β, and RANTES in lipopolysaccharide-stimulated U937 cells. Results: Area-under-the-curve (AUC) analyses confirmed that Thykamine™ inhibited secretion of the chemokines MCP-1, MIP-1α, and MIP-1β with significantly greater potency than all other agents tested. Thykamine™ also suppressed secretion of RANTES similarly to prednisone and significantly more than betamethasone, clobetasol, hydrocortisone, and pimecrolimus but less than crisaborole due to crisaborole’s elevated potency when administered at high concentration. Conclusions: Overall, Thykamine™ showed significantly greater or comparable inhibitory potency, particularly at lower concentrations, without evidence of cytotoxicity. These findings underscore the potential of Thykamine™ as a potent, multi-target anti-inflammatory therapy, which could offer substantial clinical advantages by effectively controlling chemokine-mediated inflammation with potentially fewer adverse effects. The results of this study support the need for evaluation of the clinical therapeutic efficacy of Thykamine™ in a wide range of autoimmune conditions. Full article
(This article belongs to the Special Issue Advances in Pharmacology of Pain and Inflammation)
►▼ Show Figures

Figure 1

Review

Jump to: Research

25 pages, 1683 KB  
Review
Efficacy of Locally Applied Flurbiprofen in Sore Throat Treatment: A Scoping Review
by Emili Dragaš, Dejan Tomljenović, Ivan Rašić, Ivana Jurčić Čulina, Lucija Svetina, Goran Geber, Davor Vagić and Andro Košec
Biomedicines 2025, 13(12), 3035; https://doi.org/10.3390/biomedicines13123035 - 10 Dec 2025
Cited by 2 | Viewed by 3981
Abstract
Background and Objectives: Sore throat is a common symptom that, due to its heterogeneous etiology and diverse clinical presentation, poses challenges for both accurate diagnosis and etiological treatment, making symptomatic therapy essential. Our review aims to provide an overview of the literature on [...] Read more.
Background and Objectives: Sore throat is a common symptom that, due to its heterogeneous etiology and diverse clinical presentation, poses challenges for both accurate diagnosis and etiological treatment, making symptomatic therapy essential. Our review aims to provide an overview of the literature on locally applied flurbiprofen in the treatment of sore throat of both infectious and non-infectious etiologies. Materials and Methods: The database PubMed was searched for studies evaluating the effect of flurbiprofen on sore throat in the last ten years (28 August 2025), and 15 studies were selected for the analysis based on the predefined inclusion and exclusion criteria. We analyzed the effect of flurbiprofen in acute pharyngitis on relief of pain, difficulty swallowing, throat swelling, the Qualities of Sore Throat Index, overall satisfaction scores and Upper Respiratory Tract Infection Questionnaire, stratified by single or multiple doses and concomitant antibiotics. Efficacy in postoperative sore throat treatment and safety profile were also analyzed. The results are demonstrated in tables and forest plots. Results: Topical flurbiprofen is shown to be effective in pain relief, relief of difficult swallowing and throat swelling in acute pharyngitis in both single and multiple doses, regardless of the formulations. The same effect is noted when analyzed by the Qualities of Sore Throat Index questionnaire and overall satisfaction scores. The data shows that flurbiprofen reduces related upper respiratory tract infection symptoms. It is also shown to be effective in reducing the incidence and severity of postoperative sore throat. No serious adverse effects were reported in the included studies. Conclusions: Topical flurbiprofen seems to be an effective and safe symptomatic treatment option for sore throat in both infectious and non-infectious etiologies. Full article
(This article belongs to the Special Issue Advances in Pharmacology of Pain and Inflammation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop